{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9(11)"],"submitter":["Lin MH"],"pubmed_abstract":["While pioglitazone reduces insulin resistance and hepatic gluconeogenesis effectively in patients with type 2 diabetes mellitus (T2DM), these benefits remained controversial in patients with end stage renal disease (ESRD). We compared major adverse cardiac cerebrovascular events (MACCEs) and mortality (overall, infection-related, and MACCE-related) of pioglitazone to that of dipeptidyl peptidase 4 inhibitors (DPP4-inhibitors) in patients with T2DM and ESRD. From Taiwan's national health insurance research database (NHIRD), 647 pioglitazone users and 6080 DPP4-inhibitors users between 1 April 2006 and 31 December 2016 were followed from the 91th date after the ESRD certification until the study outcomes, independently; withdraw from the NHI program, death, or 31 December 2017, whichever cam"],"journal":["Journal of clinical medicine"],"pagination":["E3578"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7694655"],"repository":["biostudies-literature"],"pubmed_title":["Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006-2016."],"pmcid":["PMC7694655"],"pubmed_authors":["Lin MH","Anderson GF","Yen CL","Wu CY","Peng WS","Tian YC","Jenq CC","Kuo G","See LC","Liu JR","Yang CW","Yang HY"],"additional_accession":[]},"is_claimable":false,"name":"Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006-2016.","description":"While pioglitazone reduces insulin resistance and hepatic gluconeogenesis effectively in patients with type 2 diabetes mellitus (T2DM), these benefits remained controversial in patients with end stage renal disease (ESRD). We compared major adverse cardiac cerebrovascular events (MACCEs) and mortality (overall, infection-related, and MACCE-related) of pioglitazone to that of dipeptidyl peptidase 4 inhibitors (DPP4-inhibitors) in patients with T2DM and ESRD. From Taiwan's national health insurance research database (NHIRD), 647 pioglitazone users and 6080 DPP4-inhibitors users between 1 April 2006 and 31 December 2016 were followed from the 91th date after the ESRD certification until the study outcomes, independently; withdraw from the NHI program, death, or 31 December 2017, whichever cam","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Nov","modification":"2025-04-19T14:55:04.653Z","creation":"2021-02-20T00:29:08Z"},"accession":"S-EPMC7694655","cross_references":{"pubmed":["33172034"],"doi":["10.3390/jcm9113578"]}}